PSP (parotid secretory protein)/SPLUNC2 (short palate, lung and nasal epithelium clone 2) is expressed in human salivary glands and saliva. The protein exists as an N-glycosylated and non-glycosylated form and both appear to induce agglutination of bacteria, a major antibacterial function for salivary proteins. Both forms of PSP/SPLUNC2 bind LPS (lipopolysaccharide), suggesting that the protein may also play an antiinflammatory role. Based on the predicted structure of PSP/SPLUNC2 and the location of known antibacterial and anti-inflammatory peptides in BPI (bactericidal/permeability-increasing protein) and LBP (LPS-binding protein), we designed GL13NH2 and GL13K, synthetic peptides that capture these proposed functions of PSP/SPLUNC2. GL13NH3 agglutinates bacteria, leading to increased clearance by macrophages and reduced spread of infection in a plant model. GL13K kills bacteria with a minimal inhibitory concentration of 5-10 μg/ml, kills bacteria in biofilm and retains activity in 150 mM NaCl and 50 % saliva. Both peptides block endotoxin action, but only GL13K appears to bind endotoxin. The peptides do not cause haemolysis, haemagglutination in serum, inhibit mammalian cell proliferation or induce an inflammatory response in macrophages. These results suggest that the GL13NH2 and the modified peptide GL13K capture the biological activity of PSP/SPLUNC2 and can serve as lead compounds for the development of novel antimicrobial and anti-inflammatory peptides.
Introduction
PSP (parotid secretory protein)/SPLUNC2 (short palate, lung and nasal epithelium clone 2) (C20orf70) is the predominant member of the PLUNC (palate, lung and nasal epithelium clone) family in saliva. PSP was originally identified in the mouse parotid gland, and it has long been recognized as a major secretory protein in rodent parotid glands [1] [2] [3] . PSP is also expressed in the mouse lacrimal gland [4] , but is not among 54 proteins identified in human tears [5] . Hamster PSP is expressed in salivary glands, and the protein was also found in high-density lipoprotein, which could indicate a functional overlap between PSP and lipid transport proteins, including CETP (cholesteryl ester-transfer protein) and phospholipid-transfer protein [6] . Horse PSP is an abundant 28 kDa protein that is expressed in salivary glands and sweat [7] . It is related to latherin, which is also expressed in these fluids [8, 9] . A group of PSP-related proteins, BSP30s (bovine salivary protein 30s) [10, 11] , are highly expressed in bovine saliva, in particular in cattle with low susceptibility to pasture bloat [12] . If confirmed, this association could point to an antibacterial or surfactant function of BSP30s in the rumen. PSP is also expressed in pig (Sus scrofa) salivary glands [13] . The high expression of PSP in salivary glands has prompted use of its promoter to specifically target transgenic phytase expression to saliva to reduce phosphorus pollution from animal manure [14] [15] [16] . PSP-related proteins have also been predicted in dog (Canis familiaris), chimpanzee (Pan troglodytes) (NCBI ID: XP_001156872), orangutan (Pongo abelii) (XP_002830248), rhesus macaque (Macaca mulatta) (XP_002830248), marmoset (Callithrix jacchus) (XP_002747268) and giant panda (Ailuropoda melanoleuca) (XP_002918340). This list suggests that PSP/SPLUNC2 may be generally required for salivary function, independent of a specific diet.
Characterization of human PSP/SPLUNC2
Human PSP/SPLUNC2 is expressed in salivary glands, saliva and gingival epithelial cells [17, 18] . In the latter cell type, PSP/SPLUNC2 expression is regulated by the Gramnegative bacteria Porphyromonas gingivalis and the proinflammatory cytokine TNFα (tumour necrosis factor α) [18] . In the human parotid gland PSP/SPLUNC2 is expressed in both acinar and ductal epithelial cells [17] . PSP/SPLUNC2 has been identified in glandular saliva from the parotid and submandibular/sublingual glands. Unlike horse, cow and rodent PSP/BSP30, the human protein is not a major band detected by SDS/PAGE of whole saliva (S.-U. Gorr, unpublished work) but the protein appears in the top 30 of over 900 salivary proteins based on the number of distinct peptides identified by proteomic analysis [19] . The functional significance of this difference between species, if any, is not known.
Human PSP/SPLUNC2 is a 249-amino-acid protein. The protein contains two N-glycosylation sites located at Asn 124 and Asn 132 [20] . The protein is typically found by immunoblotting of saliva as two major distinct bands probably representing the N-glycosylated and non-glycosylated forms. Consistent with this, we found that PSP/SPLUNC2 expressed in mammalian cells corresponds to the upper band seen in saliva, whereas PSP/SPLUNC2 expressed in Escherichia coli corresponds to the lower band [17] . In addition, the upper bands are collapsed to a lower-molecularmass band on treatment with endoglycosidase F [21] .
Based on sequence prediction analyses, databases currently identify amino acid residues 1-18 as the putative signal sequence of PSP/SPLUNC2 (e.g. UniProt ID Q96DR5). However, trypsin digests of proteins secreted in saliva (that would lack the signal peptide) contain PSP/SPLUNC2 peptides with one or two additional N-terminal residues, including T.SESLLDNLGNDLSNVVDKLEPVLHEGLET-VDNTLK.G [19] . Based on this analysis, we propose that the signal peptide of PSP/SPLUNC2 consists of residues 1-16 and the mature protein consists of residues 17-249.
Functional models for PSP/SPLUNC2
Salivary proteins typically function in wetting and digestion of food (e.g. mucins and amylase), protection and remineralization of tooth surfaces (e.g. mucin and prolinerich proteins) or host defence of the oral cavity (e.g. lysozyme and defensins) [22] . PSP/SPLUNC2 is related to the BPI (bactericidal/permeability-increasing protein)/LBP [LPS (lipopolysaccharide)-binding protein]/CETP family of mammalian lipid-binding proteins that include BPI, LBP, CETP and PLTP (phospholipid-transfer protein) [23] . Indeed, PSP/SPLUNC2 and its related proteins contain conserved cysteine residues that form a disulfide bridge in BPI. The disulfide bridge has not been verified in PSP/SPLUNC2, but a PSP/SPLUNC2 mutant lacking the cysteine residues is not secreted, suggesting that its structure is significantly altered (C. Geetha and S.-U. Gorr, unpublished work). Aside from the conserved cysteine residues, the sequence identity of PSP/SPLUNC2 and BPI is low (22 %), consistent with observations for other proteins related to the BPI family [24] . Based on the known functions of salivary proteins, the similarity of PSP/SPLUNC2 to BPI/LBP/CETP proteins and the mucosal localization of the PLUNC family, we focused our functional studies on host-defence functions of PSP/SPLUNC2. This is supported by the findings that mouse PSP binds bacteria [4] and that PLUNC exhibits anti-mycoplasma activity, antipseudomonal activity and binds LPS [25, 26] .
Antibacterial function of PSP/SPLUNC2
We initially expressed PSP/SPLUNC2 in the rat cell line GH4C1 and used the secretion medium to test the effect on the number of cfu (colony-forming units). Secretion media that contained PSP/SPLUNC2 reduced the number of colonies of Pseudomonas aeruginosa PAO1 [17] . We originally interpreted this reduction to indicate a bactericidal activity of PSP/SPLUNC2, but subsequent studies with PSPpeptides [27] indicated that bacterial agglutination also would result in a reduction in cfu. To test whether PSP/SPLUNC2 causes bacterial agglutination, the His-tagged protein was expressed in E. coli and inclusion bodies collected and solubilized (T. Wheeler, personal communication). The crude PSP/SPLUNC2 samples contained about 45 % PSP/SPLUNC2 as judged from SDS/PAGE and Coomassie Blue staining. This fraction was incubated with Ps. aeruginosa and bacterial agglutination was observed by light microscopy ( Figure 1 ). Only samples from PSP/SPLUNC2 producing cultures that had been induced with IPTG (isopropyl β-Dthiogalactoside) caused agglutination. These results support the proposal that PSP/SPLUNC2 acts as a salivary agglutinin similar to DMBT1 (deleted in malignant brain tumours 1) [27] .
Antibacterial function of PSP-peptides
Based on the predicted similarity of PSP/SPLUNC2 and the BPI/LBP proteins as well as the known location of biologically active peptides in the sequences of BPI and LBP [28] , we designed PSP/SPLUNC2 peptides with predicted antibacterial and anti-inflammatory activity. Indeed, peptides were identified that inhibit the action of LPS [29] and cause agglutination of both Gram-negative (Ps. aeruginosa, Aggregatibacter actinomycetemcomitans) and Gram-positive (Streptococcus gordonii) bacteria [27] . Agglutination may play a biological role, since the agglutinating peptide GL13NH2, (PSP 141-153) limited the spread of Ps. aeruginosa in a lettuce leaf infection model and increased the uptake of Ps. aeruginosa by macrophages [27] .
GL13NH2 did not exhibit bactericidal activity. To achieve this, the peptide was modified to increase the overall positive charge by substituting three amino acids for lysine residues ( Figure 2 ). This modified peptide (GL13K) did not exhibit agglutinating activity but, instead, exhibited bactericidal activity in a 2 h kill assay performed in 10 mM sodium phosphate (e.g. [30] ). GL13K and the control peptide polymyxin B effectively killed the Gram-negative bacteria Ps. aeruginosa, E. coli and the Gram-positive bacteria S. gordonii, whereas other PSP/SPLUNC2 peptides had no effect on bacterial survival. The bactericidal activity of GL13K was not affected by the addition of 150 mM NaCl or 50 % saliva. The minimal inhibitory concentration of GL13K, as determined by microtitre broth dilution [31, 32] , was 5-10 μg/ml against Ps. aeruginosa and E. coli.
To test whether GL13K was effective against bacteria grown in a biofilm, Ps. aeruginosa were cultured for 24 h in 96-well PVC plates, which were washed to remove planktonic bacteria. The wells were treated with GL13K or control peptides and surviving attached bacteria quantified by an ATP viability assay. GL13K and polymyxin B reduced viable Ps. aeruginosa 2566 was incubated with PSP/SPLUNC2 expressed in induced (PSP 100 μg/ml) or un-induced culture (PSP no IPTG). Bacteria only and Lactoferrin were used as controls. Bacterial agglutination was identified by light microscopy of the culture dish.
Figure 2
Sequence and side chain structure of the PSP peptides GL13NH2 (top) and GL13K (bottom)
The amino acids are oriented with hydrophilic side chains facing up and hydrophobic side chain facing down. Residues that differ between the two peptides are shown in bold.
attached bacteria by over 90 %. Other PSP-peptides or buffer alone had no effect on viability.
LPS-binding activity of PSP/SPLUNC2
PLUNC has been reported to bind LPS [25] , as expected from its structural similarity to LBP, whereas LPS binding was not detected for BSP30 [11] . To determine whether PSP/SPLUNC2 binds LPS, whole saliva samples were incubated with LPS-beads, which were then washed and analysed by immunoblotting. Both the glycosylated and unglycosylated forms of PSP/SPLUNC2 were captured by LPS and could be eluted with a non-ionic detergent, suggesting a hydrophobic interaction. Moreover, binding of PSP/SPLUNC2 to LPS was inhibited by GL13NH2, suggesting that this peptide interferes with the binding site. GL13K was not tested in this assay, but the two peptides (GL13NH2 and GL13K) inhibited the LPSstimulated secretion of TNFα from macrophages by 60 and 80 % respectively.
In preliminary experiments, we have tested the activity of GL13NH2 in a D-galactosamine-sensitized mouse sepsis model. C57BL/6 mice were sensitized with D-galactosamine and injected intraperitoneally with Ps. aeruginosa LPS. Death typically occurred in 8-10 h in this model. LPS was injected alone or in combination with GL13NH2 ( Figure 3 ). GL13NH2 increased survival in this model from 70 to 100 %.
Toxicity studies
Polymyxin is currently in clinical use for ophthalmic and skin infections. It was disused for several years due to its high toxicity [33] . Thus there is a need for novel, less toxic, antibiotics. To test the toxicity of PSPpeptides, we evaluated the lysis of sheep red blood cells, haemagglutination, survival and proliferation of mammalian cells and the inflammatory response in macrophages (TNFα secretion). While GL13NH2 caused haemagglutination in the absence of serum, none of the other assays indicated toxicity of these peptides. Importantly, all mice that received GL13NH2 survived (Figure 3 ). In addition, we maintained Caenorhabditis elegans on Ps. aeruginosa with or without GL13NH2 and observed no differences in viability or hatching of young nematode worms.
Summary
The data reviewed here strongly support a host-defence function for PSP/SPLUNC2. Indeed, we have found evidence that both the intact protein and peptides derived from the protein sequence exhibit antibacterial activity and anti-inflammatory activity. Thus these results support the biological functions that were predicted by the proposed structural similarity of PLUNC proteins and BPI/LBP. These results are also consistent with the mucosal expression of PLUNC proteins. It is important to consider, however, that the functional predictions are based on computer modelling of the PSP/SPLUNC2 sequence and that related proteins are involved in lipid binding (CETP, PLTP), juvenile hormone binding, odorant binding and olfaction. In addition, PLUNC [34] and latherin [9] display surfactant activity that may contribute to the wetting of mucosal and skin surfaces. Indeed, we have recently reported that the PSP-peptide GL13NH2 is more closely related to biologically active peptides from surfactant protein and salivary agglutinin (DMBT1) than BPI [27] . Consistent with this, we recently found that surfaces coated with GL13K exhibit an increased advancing water contact angle, as would be expected of a surfactant [35] . These, currently disparate, findings add to the facets of an interesting protein that is expressed in varying abundance in the saliva of different animals.
